BCG vaccine
- Generic Name
- BCG vaccine
- Drug Type
- Biotech
- Unique Ingredient Identifier
- 8VJE55B0VG
- Background
BCG vaccine has been investigated for the treatment of Neoplasms, Bladder Cancer, Neoplasms by Site, Urologic Diseases, and Urologic Neoplasms, among others.
- Associated Conditions
- Non-Invasive Bladder Urothelial Carcinoma, Recurrent Superficial Bladder Cancer, Tuberculosis (TB), Urothelial Carcinoma Recurrent, Carcinoma in situ of urinary bladder
BCG Vaccine for Health Care Workers as Defense Against COVID 19
- Conditions
- Coronavirus InfectionCoronavirus as the Cause of Diseases Classified ElsewhereCoronavirus
- Interventions
- Biological: Placebo Vaccine
- First Posted Date
- 2020-04-16
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Texas A&M University
- Target Recruit Count
- 659
- Registration Number
- NCT04348370
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Texas A&M Family Care Clinic, Bryan, Texas, United States
Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine
- First Posted Date
- 2020-03-31
- Last Posted Date
- 2022-06-03
- Lead Sponsor
- UMC Utrecht
- Target Recruit Count
- 1511
- Registration Number
- NCT04328441
- Locations
- 🇳🇱
Sint Maartenskliniek, Nijmegen, Gelderland, Netherlands
🇳🇱Radboud UMC, Nijmegen, Gelderland, Netherlands
🇳🇱Erasmus Medical Center, Rotterdam, Zuid-Holland, Netherlands
BCG Vaccination to Protect Healthcare Workers Against COVID-19
- Conditions
- Coronavirus Disease 2019 (COVID-19)COVID-19Respiratory IllnessCorona Virus Infection
- Interventions
- Drug: 0.9%NaCl
- First Posted Date
- 2020-03-31
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Murdoch Childrens Research Institute
- Target Recruit Count
- 6828
- Registration Number
- NCT04327206
- Locations
- 🇦🇺
Prince of Wales Hospital, Sydney, New South Wales, Australia
🇦🇺Westmead Hospital, Sydney, New South Wales, Australia
🇧🇷Fundação de Medicina Tropical Dr Heitor Vieira Dourado (FMT-HVD), Manaus, Amazonas, Brazil
PK Sub-Study of QUILT-3.032 (CA ALT-803-01-16) and of QUILT-2.005 (CA ALT-803-01-14)
- Conditions
- Pharmacokinetics
- Interventions
- Drug: N-803 alone
- First Posted Date
- 2019-10-29
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Altor BioScience
- Target Recruit Count
- 1
- Registration Number
- NCT04142359
- Locations
- 🇺🇸
Adult & Pediatric Urology, Omaha, Nebraska, United States
🇺🇸University of Miami Miller School of Medicine-Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸UCLA Department of Urology, Los Angeles, California, United States
Atezolizumab and BCG in High Risk BCG naïve Non-muscle Invasive Bladder Cancer (NMIBC) Patients (BladderGATE)
- Conditions
- Invasive Bladder Cancer
- Interventions
- First Posted Date
- 2019-10-21
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Fundacion Oncosur
- Target Recruit Count
- 40
- Registration Number
- NCT04134000
- Locations
- 🇪🇸
Hospital 12 de Octubre, Madrid, Spain
Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients
- First Posted Date
- 2019-01-10
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 517
- Registration Number
- NCT03799835
- Locations
- 🇫🇷
Hôpital Cochin, Paris, France
🇫🇷Groupe Hospitalier Paris Saint Joseph, Paris, France
🇫🇷Hôpital privé de la Louvière, Lille, France
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
- Conditions
- High-risk Non-muscle Invasive Bladder Cancer
- Interventions
- First Posted Date
- 2018-10-18
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1397
- Registration Number
- NCT03711032
- Locations
- 🇯🇵
Institute of Science Tokyo Hospital ( Site 0409), Tokyo, Japan
🇺🇸Alaska Urological Institute dba Alaska Clinical Research Center ( Site 1083), Anchorage, Alaska, United States
🇺🇸Mayo Clinic in Arizona - Phoenix ( Site 1094), Phoenix, Arizona, United States
Electromotive Mitomycin-C (EMDA-MMC) in Preventing Recurrences in High-risk Non-muscle-invasive Bladder Cancer
- Conditions
- Bladder Cancer
- Interventions
- Drug: Sequential BCG and EMDA mitomycin C
- First Posted Date
- 2018-09-11
- Last Posted Date
- 2021-04-01
- Lead Sponsor
- Turku University Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT03664869
- Locations
- 🇫🇮
Tampere University Hospital, Tampere, Finland
🇫🇮Turku University Hospital, Turku, Finland
🇫🇮Seinäjoki Central Hospital, Seinäjoki, Finland
Dose-Defining Safety and Immunogenicity Study of MTBVAC in South African Neonates
- First Posted Date
- 2018-05-24
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Biofabri, S.L
- Target Recruit Count
- 99
- Registration Number
- NCT03536117
- Locations
- 🇿🇦
SATVI: Worcester, Worcester, Western Cape, South Africa
S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer
- Conditions
- Stage 0is Bladder Urothelial CarcinomaStage 0 Bladder Urothelial CarcinomaStage I Bladder Urothelial Carcinoma
- Interventions
- Other: Laboratory Biomarker Analysis
- First Posted Date
- 2017-03-27
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 1000
- Registration Number
- NCT03091660
- Locations
- 🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸Marshfield Clinic-Wausau Center, Wausau, Wisconsin, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.